ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV)...

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...